Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Buys 555,556 Shares of Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Denise P. Carter bought 555,556 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $0.45 per share, with a total value of $250,000.20. Following the transaction, the chief operating officer now directly owns 602,648 shares in the company, valued at $271,191.60. This represents a 1,179.72 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ QNRX traded down $0.01 during mid-day trading on Friday, hitting $0.55. 553,804 shares of the stock were exchanged, compared to its average volume of 1,118,553. Quoin Pharmaceuticals, Ltd. has a twelve month low of $0.43 and a twelve month high of $6.18. The company has a market cap of $2.78 million, a P/E ratio of -0.14 and a beta of 1.79. The stock’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.63.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.